About Us

The management team is highly accomplished in pharmaceutical development and in creating significant enterprise value. In particular, the CEO, Chris Prior, Ph.D., has created liquidity opportunities with his last four companies, two M&As and two IPOs, while the CMO, Daniel Vlock, M.D., has also built and sold a biopharm company. Together, exits achieved by these two executives exceed $1 Billion.

Meet The Team

Chris Prior, Ph.D. – Chief Executive Officer & Executive Chairman of the Board of Directors

 

35+ years in pharmaceutical development; 25 INDs; 4 product approvals; founded and sold two biopharma companies (Principia, BioRexis) with exits exceeding $500 million; Raised $75 million as CEO of PhaseBIO; took Innovate Biopharmaceuticals 4 public; director of R&D at Aventis (now Sanofi), senior product development scientist at Biogen (7th
employee).

Daniel Vlock, MD., Chief Medical Officer

 

A board certified medical oncologist with a distinguished academic career (Yale, Harvard, Cornell) and 25+ years of pharmaceutical industry experience. He has held Director and Vice President positions at Boehringer Ingelheim, Pharmacia, Ariad and other biopharmaceutical companies before founding his own company, Alopexx Enterprises, LLC. That company successfully licensed its technology to Sanofi for $375 million. Dr. Vlock has had responsibility for
numerous clinical development programs including pivotal, multi-center Phase III studies.

Jeff Davidson, B.S. Ch. E., MBA – Chief Operating Officer 

Co-founderraised $15.5 million for Pendrea; led development of the product pipeline, cGMP manufacturing, clinical and partnering programs. Previously, Founder of Life Sciences PA, a trade industry organization with over 800 members. Also Founder and Executive Director of BIO’s Biotechnology Institute.

James Sharpe, BS Chem, MBA -- Chief Business Officer

 

Prior positions include Founder and CEO of an immuno-oncology company, President of a drug discovery company, COO of a drug delivery company and CEO of a public biopharm company. He also served as Director of Marketing for Centocor, Inc., Director of Business Development for Benzon Pharma A/S, and Director, Strategic Planning for the $1 Billion Health Sciences
Division of Eastman Kodak Co.

Buckner Brown, MBA, CPA -- Chief Financial Officer

 

Senior financial executive with more than 40 years of investment banking and public accounting experience. Have represented clients in more than $10 billion of financing and M&A transactions. Licensed securities industry professional with significant experience raising capital for early-stage
companies

James Adair, Ph.D. - Chief Science Officer

Co-founder, Professor of Material Science, Penn State University, developer of NanoJacket technologies and a leading nanoparticle expert.

Mark Kester, Ph.D. - Chief Technology Officer

 

Co-founder, Director of NanoStar Institute, University of Virginia, developer of Ceraxa and a leading Ceramide researcher.